Palisade Bio (NASDAQ:PALI) Director Purchases 25,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 25,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were bought at an average cost of $1.96 per share, for a total transaction of $49,000.00. Following the acquisition, the director owned 461,904 shares in the company, valued at approximately $905,331.84. The trade was a 5.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 8th, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.99 per share, with a total value of $39,800.00.
• On Tuesday, July 7th, Robert Jr. Baltera acquired 30,000 shares of Palisade Bio stock. The shares were bought at an average cost of $2.03 per share, with a total value of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The shares were bought at an average price of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was bought at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Trading Down 0.5%

NASDAQ:PALI traded down $0.01 during trading hours on Friday, reaching $1.96. The company had a trading volume of 3,452,719 shares, compared to its average volume of 4,120,886. The firm has a market cap of $340.22 million, a price-to-earnings ratio of -1.94 and a beta of 1.50. The firm’s 50 day moving average price is $1.92 and its 200-day moving average price is $1.92. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, analysts forecast that Palisade Bio, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on PALI. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a research report on Tuesday, June 30th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Finally, Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palisade Bio presently has an average rating of “Buy” and an average target price of $8.83.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Commodore Capital LP purchased a new stake in Palisade Bio in the fourth quarter worth about $26,896,000. Creek Drive Management Group LLC bought a new position in shares of Palisade Bio in the fourth quarter worth about $723,000. Perceptive Advisors LLC purchased a new position in shares of Palisade Bio during the 4th quarter valued at about $28,318,000. Artia Global Partners LP purchased a new position in shares of Palisade Bio during the 4th quarter valued at about $4,682,000. Finally, BIT Capital GmbH bought a new position in shares of Palisade Bio during the 4th quarter valued at approximately $717,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.